ELANE rs17223045C/T and rs3761007G/A variants: Protective factors against COVID-19

Authors

  • José Manuel Fragoso Laboratorio de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico https://orcid.org/0000-0003-3137-7815
  • Gilberto Vargas-Alarcón Dirección de Investigación, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico https://orcid.org/0000-0001-7916-5163
  • Ángel Emmanuel Martínez-Flores Unidad de Investigación, Hospital Juárez de México, México City, México https://orcid.org/0009-0003-2776-2929
  • Isela Montufar-Robles Unidad de Investigación, Hospital Juárez de México, Mexico City, Mexico https://orcid.org/0000-0002-1141-452X
  • Rosa Elda Barbosa-Cobos Servicio de Reumatología, Hospital Juárez de México, Mexico City, Mexico
  • Gustavo Rojas-Velasco Unidad de Cuidados Intensivos, Instituto Nacional de Cardiología Ignacio Chávez, México City, México
  • Julian Ramírez-Bello Subdirección de Investigación Clínica, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico https://orcid.org/0000-0002-4153-9315

DOI:

https://doi.org/10.17305/bb.2023.9940

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for causing coronavirus disease 2019 (COVID-19). The development and severity of this infectious disease is influenced by a combination of environmental and genetic factors. Angiotensin-converting enzyme 2 (ACE2) facilitates SARS-CoV-2 entry into human cells, with transmembrane serine protease 2 (TMPRSS2) playing a crucial role in S protein priming. Other proteases, such as cathepsin L and elastase, neutrophil-expressed (ELANE), have the capability to prime the S protein and contribute to SARS-CoV-2 infection. ELANE variants have not been previously examined in COVID-19 patients. We aimed to assess the association of single nucleotide variants (SNVs) within ELANE with COVID-19 and biochemical markers. The study included 319 SARS-CoV-2-infected patients and 288 controls. Genotyping of ELANE rs17216663C/T (Pro257Leu), rs17223045C/T (As1n30Asn), and rs3761007G/A was conducted using a 5'-nuclease allelic discrimination assay (TaqMan assay). Our findings indicate that ELANE rs17223045C/T (C vs T: odds ratio [OR] 0.08, P = 0.005, and CC vs CT: OR 0.08, P = 0.005) and rs3761007G/A (G vs A: OR 0.38, P = 0.009, and GG vs GA: OR 0.40, P = 0.008) confer protection against COVID-19. However, these variants were not associated with biochemical markers. In conclusion, our data suggests that ELANE rs17223045C/T and rs3761007G/A SNVs may play a protective role against COVID-19.

Author Biographies

  • Ángel Emmanuel Martínez-Flores, Unidad de Investigación, Hospital Juárez de México, México City, México

    Unidad de Investigación. Hospital Juárez de México

  • Julian Ramírez-Bello, Subdirección de Investigación Clínica, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico

    Subdirección de Investigación Clínica, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico

Downloads

Published

15-01-2024

Issue

Section

New and Emerging Medical Entities

Categories

How to Cite

1.
ELANE rs17223045C/T and rs3761007G/A variants: Protective factors against COVID-19. Biomol Biomed [Internet]. 2024 Jan. 15 [cited 2024 Mar. 3];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/9940